Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers

Omega-3 Fatty Acid Supplementation to Prevent Preterm Birth in High Risk Pregnancies

ClinicalTrials.gov ID: NCT00135902

Public ClinicalTrials.gov record NCT00135902. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Trial of Omega-3 Fatty Acid Supplementation to Prevent Preterm Birth in Pregnancies at High Risk

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A recently completed trial of weekly injections of 17 alpha hydroxyprogesterone caproate (17P) found significant effectiveness for 17P in preventing recurrent preterm birth. However, the group who received 17P in this trial still had a high rate of preterm birth. Several reports have shown that dietary supplementation of fish oil, which is rich in Omega-3 fatty acids, reduces the risk of preterm birth. This trial tests whether adding the Omega-3 supplement to 17P therapy has the potential for further reducing the risk of preterm birth in women who have previously had a spontaneous preterm delivery. The trial will compare Omega-3 fatty acid with placebo in women receiving 17P therapy. The hypothesis being tested is: "Among women at high risk for preterm birth receiving weekly injections of 17P, the addition of Omega-3 nutritional supplement will further reduce the rate of preterm birth."

Study identification

NCT ID
NCT00135902
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
800 participants

Conditions and interventions

Eligibility (public fields only)

Age range
Not listed
Sex
Female
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2005
Primary completion
Feb 28, 2007
Completion
Feb 29, 2008
Last update posted
Jul 11, 2019

2005 – 2008

United States locations

U.S. sites
12
U.S. states
9
U.S. cities
12
Facility City State ZIP Site status
University of Alabama - Birmingham Birmingham Alabama
Northwestern University Chicago Illinois
Wayne State University Detroit Michigan
Columbia University New York New York
University of North Carolina - Chapel Hill Chapel Hill North Carolina
Wake Forest University School of Medicine Winston-Salem North Carolina
Case Western University Cleveland Ohio
Ohio State University Columbus Ohio
Drexel University Philadelphia Pennsylvania
University of Pittsburgh Magee Womens Hospital Pittsburgh Pennsylvania
Brown University Providence Rhode Island
University of Utah Medical Center Salt Lake City Utah

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00135902, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 11, 2019 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00135902 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →